Navigation Links
Divergence Raises $11.8 Million in Series C Financing
Date:2/11/2009

Biotechnology firm Divergence, Inc., a world leader in developing products for the control of parasites in agriculture and medicine, today announced that it has raised $11.8 million in a Series C financing round that will further its efforts to create solutions for one of the major causes of crop yield loss for farmers.

St. Louis, MO (PREWB) February 11, 2009 -- Biotechnology firm Divergence, Inc., a world leader in developing products for the control of parasites in agriculture and medicine, today announced that it has raised $11.8 million in a Series C financing round that will further its efforts to create solutions for one of the major causes of crop yield loss for farmers.

MidPoint Food and Ag Fund LP acted as lead investor in the round. Other institutional investors included Prolog Ventures LP and certain partners of William Blair & Co. The round included 41 returning investors including all members of Divergence's Board of Directors. The financing more than doubles the amount of equity capital raised by the company since its inception.

Proceeds from the financing will be used to advance Divergence's nematicide program. The company is developing molecules for the control of plant parasitic nematodes. Nematode control is the largest unsolved pest problem in agriculture limiting the yield of crops worldwide and causing billions of dollars in crop damage annually. Divergence has discovered the first novel mode of action for this market in more than 20 years. The new molecules feature human and environment safety profiles that are vastly superior to traditional nematicides. The funding will also support the Company's continued development of crops that are resistant to nematodes, as well as its innovative, broad-based research platforms Harvest™, STEM™ and RNA interference.

"This financing, especially given the sophistication of the participating investors, provides further validation of Divergence's revolutionary technology and the rapid advancements of our projects in parasite control," said Derek K. Rapp, Chief Executive Officer of Divergence. "Through our internal programs and corporate alliances in crop protection and animal health, Divergence is committed to the development of parasite control products for higher yielding agriculture and healthier people and animals. Upon the completion of this financing, Ronald L. Meeusen, Ph.D., Partner of Midpoint Food & Ag Fund, LP, will join the Divergence Board of Directors. Dr. Meeusen brings to Divergence more than 25 years of corporate experience in agricultural biotechnology. "There is tremendous value in the cutting-edge science of Divergence," said Dr. Meeusen. "As the first company in our investment portfolio, Divergence exemplifies our goal to invest in companies that can enable environmentally sustainable agriculture and offer promise for human and animal wellness."

With the addition of Dr. Meeusen, the Board of Directors of Divergence stands at seven people - Stanford J. Goldblatt, Partner and Head of the Private Equity Practice at Winston & Strawn; James P. McCarter, M.D., Ph.D., President and Chief Scientific Officer of Divergence; John W. McCarter, Jr., President and CEO of the Field Museum in Chicago; Ronald L. Meeusen, Ph.D., Partner of MidPoint Food and Ag Fund, LP; Ilya B. Nykin, Managing Director of Prolog Ventures; Derek K. Rapp, Chief Executive Officer of Divergence; and Mark W. Wong, President and CEO of Agrivida, Inc.

About Divergence:
Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease, discovers and develops products for the safe and effective control of parasites. The company's initial focus is on parasitic nematodes, devastating unseen pests that cause billions of dollars in crop loss annually and widespread disease in humans and animals. For more information visit Divergence's Web site at www.divergence.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/02/prweb2027334.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
2. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
3. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
4. Anacor Raises $50 Million in Equity Financing
5. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile
6. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
7. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
8. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
9. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
10. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
11. MacroGenics Raises $25M in Series D-2 Financing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Divergence Raises $11.8 Million in Series C Financing
(Date:1/18/2017)... 18, 2017  HUYA Bioscience International, (HUYA), the leader ... pharmaceutical innovations, announced today a strategic collaboration ... Investment Company (referred to as CAS Innovation). The collaboration ... by leading scientists at CAS to meet the medical ... is the first company to have recognized ...
(Date:1/18/2017)... 2017 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; ... that develops and commercializes proprietary technologies and products ... today announced that Cameron Prange , President ... from its Board of Directors.  Mr. Prange,s resignation ... that have limited both his ability to act ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC Maine Standards ... VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates Albumin, C-reactive ... SP2 kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:1/17/2017)... , Jan. 17, 2017 The ... at a CAGR of around 7.5% over the ... 2025. Some of the prominent trends that the ... incidences of diseases & graft transplant surgeries and ... Material the market is categorized into immunomodulatory biomaterials, ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... 15, 2016 Advancements in biometrics ... wellness and wellbeing (HWW), and security of ... new passenger vehicles begin to feature fingerprint ... heart beat monitoring, brain wave monitoring, stress ... and pulse detection. These will be driven ...
Breaking Biology News(10 mins):